The US Food and Drug Administration (FDA) has approved AstraZeneca’s Baxfendy (baxdrostat) as a first-in-class hypertension therapy designed for patients living with uncontrolled high blood pressure. The US approval for AstraZeneca hypertension drug “Baxfendy” marks a major milestone in cardiovascular medicine, offering new hope to millions of adults whose blood pressure remains high despite existing medications.
According to AstraZeneca, the treatment will be used alongside standard antihypertensive medicines to help lower blood pressure in adults with uncontrolled or resistant hypertension.
Before the US FDA decision, the United Arab Emirates became the first country to approve Baxfendy by AstraZeneca earlier this month. With this decision, the UAE became the First country to approve Baxfendy.
The growing international support for the drug highlights increasing demand for resistant hypertension treatment options globally. The approval by both the US and UAE is being viewed as a significant breakthrough in hypertension medication after decades of limited innovation in the field.
AstraZeneca’s Baxfendy Introduces a New Hypertension Treatment Option
Unlike traditional blood pressure medicines, AstraZeneca’s Baxfendy works by blocking aldosterone production. Aldosterone is a hormone that causes the body to retain sodium and water, which can raise blood pressure and increase the risk of heart and kidney disease.
Baxfendy belongs to a class called aldosterone synthase inhibitors (ASI), making it the first FDA-approved blood pressure medicine in this category.
This mechanism makes the new hypertension medication by AstraZeneca different from commonly used treatments such as:
- ACE inhibitors
- Diuretics
- Calcium channel blockers
According to the company, AstraZeneca’s Baxfendy drug specifically targets one of the root hormonal causes behind persistently high blood pressure. Baxfendy may also have future applications in chronic kidney disease and heart failure.
How Did The FDA Approve the Hypertension Drug By AstraZeneca
The FDA approval for AstraZeneca hypertension drug was based on results from the BaxHTN Phase III trial, which evaluated patients with uncontrolled or resistant hypertension already taking two or more medications.
The study demonstrated clinically meaningful reductions in systolic blood pressure, which is the pressure in arteries when the heart beats. The results were published in the New England Journal of Medicine.
Key findings from the BaxHTN Phase III trial included:
- Baxfendy 2mg lowered systolic blood pressure by 15.7 mmHg from baseline
- The placebo-adjusted reduction was 9.8 mmHg
- The 1mg dose achieved an 8.7 mmHg placebo-adjusted reduction
- Benefits were seen across uncontrolled and resistant hypertension groups
Researchers also reported that the treatment was generally well-tolerated by patients, with no unexpected safety concerns identified during the study.
Dr. Bryan Williams, Chair of Medicine at University College London and primary investigator of the trial, said in the company statement, “We have been waiting for an innovative medication like Baxfendy for hypertension for many years.”
He added that the nearly double-digit placebo-adjusted blood pressure reduction was “clinically meaningful” for both physicians and patients.
Major Breakthrough In Resistant Hypertension
Hypertension affects nearly 1.4 billion people worldwide and remains one of the leading causes of heart attack, stroke, kidney disease, and premature death.
In the United States alone, nearly half of patients already taking multiple blood pressure medications still struggle with uncontrolled hypertension, according to AstraZeneca.
Health experts say even modest reductions in systolic blood pressure can significantly lower cardiovascular risk. Data referenced in the trial showed that reducing systolic blood pressure by 10 mmHg may lower the risk of serious cardiovascular events by around 20%.
John M. Clymer, Executive Director of the National Forum for Heart Disease & Stroke Prevention, called hypertension a “silent killer” in AstraZeneca’s announcement and emphasized the urgent need for innovative treatment options.
New Hypertension Drug Approval Expands AstraZeneca’s Cardiovascular Portfolio
The FDA’s approval of AstraZeneca blood pressure drug strengthens the company’s growing cardiovascular and renal medicine business.
AstraZeneca acquired baxdrostat through its $1.8 billion purchase of CinCor Pharma in 2023. Industry analysts expect Baxfendy to become a major commercial product in the cardiovascular market.
The approval also positions AstraZeneca ahead of competitor Mineralys Therapeutics, which is developing a rival aldosterone-targeting therapy currently under US regulatory review.
As one of the leading global pharmaceutical companies, AstraZeneca BioPharmaceutical Company continues to expand its cardiovascular innovation pipeline.
Conclusion
The US approval for AstraZeneca hypertension drug Baxfendy could reshape the treatment landscape for patients whose blood pressure remains uncontrolled despite current therapies.
As the first-in-class hypertension therapy targeting aldosterone production directly, Baxfendy represents a new scientific approach to managing one of the world’s most common chronic diseases.
Healthcare experts will now closely watch how widely the FDA-approved blood pressure medicine is adopted in clinical practice and whether ongoing studies confirm its broader cardiovascular and kidney health benefits.
